Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07011797 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants
A Phase 2 study of Obesity, sponsored by Corxel Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
- 17
- Study locations
NCT07011797 is a Phase 2 study of Obesity that is active but no longer recruiting, run by Corxel Pharmaceuticals. The registered enrollment target is 250 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (69% lower). The trial reports 17 study locations across 8 states.
The verdict
NCT07011797, a Phase 2 study of Obesity, is active but no longer recruiting, sponsored by Corxel Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study: * To evaluate the efficacy of different dose levels of CX11 tablets in body weight reduction as compared to placebo. * To compare the changes of effects in weight and weight-related indicators at the visit time points. * To evaluate the tolerability and safety of different doses of CX11 tablets in overweight/obese participants. * To assess the pharmacokinetics (PK) of different doses of CX11 tablets in overweight/obese participants. Overweight/obese participants who are successfully screened will be randomized in a 1:1:1:1:1 ratio to different doses of CX11 tablets or placebo. All participants will enter a 2-week follow-up period after 36 weeks of treatment for safety observation.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG CX11
Study Locations (17)
Florida
- Angels Clinical Research Institute - Miami - Doral
- AES - DRS - Optimal Research Florida - Melbourne - Melbourne
- Angels Clinical Research Institute - Miami
- Palm Springs Community Health Center - Miami Lakes
- Oceanic Research Group, LLC - North Miami Beach
Texas
- Velocity Clinical Research - Dallas - PPDS - Dallas
- Epic Clinical Research - Alliance Clinical - Lewisville - Lewisville
- AES - DRS - Synexus Clinical Research US, Inc. - San Antonio - San Antonio
- Flourish Research - San Antonio - PPDS - San Antonio
California
- 310 Clinical Research - Alliance Clinical - Los Angeles - Inglewood
- Acclaim Clinical Research - Alliance Clinical - San Diego - San Diego
Georgia
- Privia Medical Group Georgia, LLC - Savannah - Javara - PPDS - Savannah
- Privia Medical Group Georgia, LLC - Thomasville - Javara - PPDS - Thomasville
Arizona
- AES - DRS - Synexus Clinical Research US, Inc. - Phoenix Central - Phoenix
Indiana
- Velocity Clinical Research - Valparaiso (Buynak Clinical Research) - PPDS - Valparaiso
Minnesota
- Mankato Clinic - East Main Street - Javara - PPDS - Mankato
Ohio
- Velocity Clinical Research - Cincinnati (Springdale) - Ohio - PPDS - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2025-06-17 |
| Est. Completion | 2026-04-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07011797
The ClinicalTrials.gov registry entry for NCT07011797 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (69% lower). The listed sponsor is Corxel Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07011797 reports 17 study locations spanning 8 distinct geographic areas - top geographies include Florida, Texas, California.
Frequently Asked Questions
What is clinical trial NCT07011797 about?
NCT07011797 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants". This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study: * To evaluate the efficacy of different dose levels of CX11 tablets in body weight reduction as compared to placebo. * To compare the changes of effects in weight and weight-related indicators at the visit t...
What is the current status of trial NCT07011797?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2025-06-17. Estimated completion is 2026-04-06.
What conditions does trial NCT07011797 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT07011797?
The interventions under investigation include: Placebo (OTHER), CX11 (DRUG).
Who is sponsoring clinical trial NCT07011797?
This trial is sponsored by Corxel Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07011797 being conducted?
This trial has 17 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.